CNS Pharmaceuticals holds annual meeting, shareholders expand equity plan

CNS Pharmaceuticals, Inc. disclosed in an 8-K filing that it held its Annual Meeting at 12:00 p.m. ET on September 30, 2026.¹ The filing states that as of August 10, 2026, the record date for the Annual Meeting, there were 1,461,449 shares of common stock issued and outstanding and entitled to vote, of which 668,188, or 45.72%, were present in person or represented by proxy, constituting a quorum.¹

Shareholders approved amendments to the company's 2020 Equity Plan. According to the filing, the stockholders approved amendments to the 2020 Equity Plan including an increase in the number of shares of common stock authorized for issuance under the plan by 650,000 shares.¹ As a result, the number of shares of common stock that may be issued under the 2020 Plan, as amended, is 765,061 shares, including the 650,000 share increase.¹

On director elections, the filing reports that stockholders elected Faith Charles, Bettina Cockroft, Michal Fisher, Jeffrey Keyes, Rami Levin and Amy Mahery as directors of the Company until the 2027 Annual Meeting of Stockholders, or until their respective successors have been duly elected and qualified.¹

Shareholders also ratified MaloneBailey, LLP as the company's auditor. The filing states that stockholders ratified the appointment of MaloneBailey, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.¹

In addition, stockholders approved, on an advisory basis, a resolution on the compensation paid to the Company's executive officers,¹ and authorized adjournment of the Annual Meeting if necessary to solicit additional proxies for any proposal lacking sufficient votes.¹

The 8-K was signed by Rami Levin, identified in the filing as Chief Executive Officer and President, and dated October 1, 2026.